83861-29-4|GYKI-14451 sulfate|tert-butyl ((R)-1-((S)-2-(((S)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate hemisulfate|-范德生物科技公司

GYKI-14451 sulfate

NMR下载 COA and HPLC MSDS下载
names：
tert-butyl ((R)-1-((S)-2-(((S)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate hemisulfate
CAS号：
83861-29-4
MDL Number：
MF(分子式)： C50H78N12O14S MW(分子量)： 1103.304
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	GYKI-14451 sulfate
英文别名	GYKI-14451; GYKI 14451; GYKI14451; GYKI-14,451; GYKI 14,451; GYKI14,451; LY-178207; LY178207; LY 178207; Boc-D-Phe-Pro-Arg-H.
CAS号	83861-29-4
SMILES	O=C(N[C@H](C=O)CCCNC(N)=N)[C@H]1N(C([C@@H](CC2=CC=CC=C2)NC(OC(C)(C)C)=O)=O)CCC1.O=C(N[C@H](C=O)CCCNC(N)=N)[C@H]3N(C([C@@H](CC4=CC=CC=C4)NC(OC(C)(C)C)=O)=O)CCC3.O=S(O)(O)=O
Inchi	InChI=1S/2C25H38N6O5.H2O4S/c21-25(2,3)36-24(35)30-19(15-17-9-5-4-6-10-17)22(34)31-14-8-12-20(31)21(33)29-18(16-32)11-7-13-28-23(26)27;1-5(2,3)4/h24-6,9-10,16,18-20H,7-8,11-15H2,1-3H3,(H,29,33)(H,30,35)(H4,26,27,28);(H2,1,2,3,4)/t2*18-,19+,20-;/m00./s1
InchiKey	QTXYFTMWQXMAQW-DCBJEQAZSA-N
分子式 Formula	C50H78N12O14S
分子量 Molecular Weight	1103.304
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	GYKI-14451 sulfate(CAS:83861-29-4 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	GYKI-14451, also known as LY-178207, is a synthetic tripeptide inhibitor of thrombin with anti-atherosclerotic activity.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Callas DD, Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy. Thromb Res. 1995 Jun 1;78(5):457-60. PubMed PMID: 7544924.

[2]Callas D, Iqbal O, Fareed J. Comparison of the anticoagulant activities of thrombin inhibitors as assessed by thromboelastographic analysis. Semin Thromb Hemost. 1995;21 Suppl

4:76-9. PubMed PMID: 8747693.

[4]Callas D, Bacher P, Iqbal O, Hoppensteadt D, Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res. 1994 May 1;74(3):193-205. PubMed PMID: 8042188.

[5] Barabas E, Szell E, Bajusz S. Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagul Fibrinolysis. 1993 Apr;4(2):243-8. PubMed PMID: 8499562.

5: Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol. 1993 Apr;21(4):587-94. PubMed PMID: 7681904.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开